

# Robert P Frantz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9157924/publications.pdf>

Version: 2024-02-01

158  
papers

12,522  
citations

38660

50  
h-index

25716

108  
g-index

160  
all docs

160  
docs citations

160  
times ranked

10287  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive echocardiographic evaluation of the right heart in patients with pulmonary vascular diseases: the PVDOMICS experience. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 958-969.	0.5	6
2	Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 35-46.	5.2	17
3	Transcatheter Nonductal Reverse Potts Shunt Creation in Pulmonary Arterial Hypertension. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS121011315.	1.4	6
4	Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 751-760.	2.5	27
5	Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry. <i>Journal of the American Heart Association</i> , 2022, 11, e024969.	1.6	50
6	ISHLT consensus statement: Perioperative management of patients with pulmonary hypertension and right heart failure undergoing surgery. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 1135-1194.	0.3	17
7	Obesity in Pulmonary Arterial Hypertension. The Pulmonary Hypertension Association Registry. <i>Annals of the American Thoracic Society</i> , 2021, 18, 229-237.	1.5	18
8	EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR. <i>European Respiratory Journal</i> , 2021, 57, 2000414.	3.1	24
9	Prediction of Health-related Quality of Life and Hospitalization in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 761-764.	2.5	12
10	United States Pulmonary Hypertension Scientific Registry. <i>Chest</i> , 2021, 159, 311-327.	0.4	25
11	Cardiac and Lung Transplantation and the Right Heart. , 2021, , 317-329.		0
12	Heart-After-Liver Transplantation Attenuates Rejection of Cardiac Allografts in Sensitized Patients. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1331-1340.	1.2	18
13	Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1472-1487.	2.5	68
14	Impact of Right Ventricular Dysfunction on Short-term and Long-term Mortality in Sepsis. <i>Chest</i> , 2021, 159, 2254-2263.	0.4	33
15	REPLACE and the role of riociguat in pulmonary arterial hypertension therapy. <i>Lancet Respiratory Medicine</i> , 2021, 9, 546-547.	5.2	6
16	Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry. <i>Pulmonary Circulation</i> , 2021, 11, 1-10.	0.8	17
17	Topic-Based, Recent Literature Review on Pulmonary Hypertension. <i>Mayo Clinic Proceedings</i> , 2021, 96, 3109-3121.	1.4	6
18	Evaluation and management of patients with chronic thromboembolic pulmonary hypertension - consensus statement from the ISHLT. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1301-1326.	0.3	36

#	ARTICLE	IF	CITATIONS
19	Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type 5 inhibitors. <i>Pulmonary Circulation</i> , 2020, 10, 1-11.	0.8	15
20	Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents. <i>Chest</i> , 2020, 157, 955-965.	0.4	26
21	Outcomes After Noncardiac Surgery for Patients with Pulmonary Hypertension: A Historical Cohort Study. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2020, 34, 1506-1513.	0.6	20
22	Inpatient Palliative Care Use in Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2020, 158, 2568-2578.	0.4	20
23	Rebuttal From Dr Frantz. <i>Chest</i> , 2020, 157, 768-769.	0.4	0
24	Pulmonary Arterial Hypertension "Symptoms and Impact Questionnaire: feasibility of utilizing one-day versus seven-day symptom reporting. <i>Pulmonary Circulation</i> , 2020, 10, 1-9.	0.8	5
25	Comprehensive Diagnostic Evaluation of Cardiovascular Physiology in Patients With Pulmonary Vascular Disease. <i>Circulation: Heart Failure</i> , 2020, 13, e006363.	1.6	27
26	COUNTERPOINT: Should the New Definition of PH Be the Clinical Practice Standard? No. <i>Chest</i> , 2020, 157, 766-768.	0.4	3
27	Matepair sequencing identifies a cryptic <i>BMPR2</i> mutation in hereditary pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2020, 10, 1-4.	0.8	1
28	Diastolic Pulmonary Gradient as a Predictor of Right Ventricular Failure After Left Ventricular Assist Device Implantation. <i>Journal of the American Heart Association</i> , 2019, 8, e012073.	1.6	21
29	Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: Initial Single-Center Experience. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2019, 3, 311-318.	1.2	29
30	Predicting Survival in Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2019, 156, 323-337.	0.4	408
31	Early intervention: should we conduct therapeutic trials for mild pulmonary hypertension before onset of symptoms?. <i>Pulmonary Circulation</i> , 2019, 9, 204589401984561.	0.8	6
32	Novel Left Heart Catheterization Ramp Protocol to Guide Hemodynamic Optimization in Patients Supported With Left Ventricular Assist Device Therapy. <i>Journal of the American Heart Association</i> , 2019, 8, e010232.	1.6	17
33	Predictors and Clinical Outcomes of Vasoplegia in Patients Bridged to Heart Transplantation With Continuous-Flow Left Ventricular Assist Devices. <i>Journal of the American Heart Association</i> , 2019, 8, e013108.	1.6	19
34	Long-term results of the DELIVER for Pulmonary Arterial Hypertension trial. <i>Pulmonary Circulation</i> , 2019, 9, 204589401987861.	0.8	12
35	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. <i>Lancet Respiratory Medicine</i> , 2019, 7, 227-238.	5.2	122
36	Risk stratification and medical therapy of pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1801889.	3.1	614

#	ARTICLE	IF	CITATIONS
37	Thrombocytopenia independently predicts death in idiopathic PAH. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2019, 48, 34-38.	0.8	11
38	Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2018, 154, 126-135.	0.4	40
39	Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant Recipients. <i>Journal of the American College of Cardiology</i> , 2018, 71, 636-650.	1.2	81
40	Use of supplemental oxygen in patients with pulmonary arterial hypertension in REVEAL. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 948-955.	0.3	18
41	The prognostic significance of tricuspid valve regurgitation in pulmonary arterial hypertension. <i>Clinical Respiratory Journal</i> , 2018, 12, 1572-1580.	0.6	34
42	Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated With Heart Failure and Preserved or Reduced Ejection Fraction. <i>Circulation</i> , 2018, 137, 1796-1810.	1.6	223
43	Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 696-705.	0.3	28
44	Response. <i>Chest</i> , 2018, 154, 1262-1264.	0.4	0
45	Hypercholesterolemia after conversion to sirolimus as primary immunosuppression and cardiac allograft vasculopathy in heart transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 1372-1380.	0.3	11
46	Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire. <i>Chest</i> , 2018, 154, 848-861.	0.4	41
47	Integrated Use of Perfusion SPECT/CTA Fusion Imaging and Pulmonary Balloon Angioplasty for Chronic Pulmonary Thromboembolism. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 532-534.	1.1	6
48	Unraveling the RV Ejection Doppler Envelope. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 1268-1277.	2.3	40
49	Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI Cardiovascular Medical Research and Education Fund Workshop Report. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1661-1670.	2.5	59
50	Early Gains in Renal Function Following Implantation of HeartMate II Left Ventricular Assist Devices May Not Persist to One Year. <i>ASAIO Journal</i> , 2017, 63, 401-407.	0.9	10
51	Transition of Intravenous Treprostinil to Oral Therapy in a Patient with Functional Class IV Chronic Thromboembolic Pulmonary Hypertension. <i>Pharmacotherapy</i> , 2017, 37, e76-e81.	1.2	12
52	Totally Implantable IV Treprostinil Therapy in Pulmonary Hypertension Assessment of the Implantation Procedure. <i>Chest</i> , 2017, 152, 1128-1134.	0.4	16
53	PVDOMICS. <i>Circulation Research</i> , 2017, 121, 1136-1139.	2.0	113
54	Positioning Newer Agents: Riociguat, Selexipag, and Oral Treprostinil in the Current Landscape. <i>Advances in Pulmonary Hypertension</i> , 2017, 15, 193-197.	0.1	0

#	ARTICLE	IF	CITATIONS
55	Characterization of Prostacyclin-associated Leg Pain in Patients with Pulmonary Arterial Hypertension. <i>Annals of the American Thoracic Society</i> , 2017, 14, 206-212.	1.5	6
56	Resolution of severe pulmonary arterial hypertension complicating adult-onset Still's disease. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 1140-1144.	0.3	4
57	Usefulness of High-Density Lipoprotein Cholesterol to Predict Survival in Pulmonary Arterial Hypertension. <i>American Journal of Cardiology</i> , 2016, 118, 292-297.	0.7	22
58	Pulmonary Hypertension in Hereditary Hemorrhagic Telangiectasia. <i>Chest</i> , 2016, 149, 362-371.	0.4	31
59	Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System. <i>Chest</i> , 2016, 150, 27-34.	0.4	48
60	Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73). <i>BMJ</i> , 2016, 353, i1246.	3.0	266
61	Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience. <i>World Journal of Transplantation</i> , 2016, 6, 380.	0.6	56
62	The Future of Pulmonary Hypertension. , 2016, , 359-367.		0
63	Hospitalization and Survival in Patients Using Epoprostenol for Injection in the PROSPECT Observational Study. <i>Chest</i> , 2015, 147, 484-494.	0.4	35
64	Pulmonary arterial hypertension or left heart disease with pulmonary hypertension? Toward noninvasive clarity, but time for a new paradigm. <i>European Respiratory Journal</i> , 2015, 46, 299-302.	3.1	6
65	Submaximal Exercise Pulmonary Gas Exchange in Left Heart Disease Patients With Different Forms of Pulmonary Hypertension. <i>Journal of Cardiac Failure</i> , 2015, 21, 647-655.	0.7	20
66	Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1366-1375.	0.3	103
67	Dramatic and sustained responsiveness of pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension to vasodilator therapy. <i>Respiratory Medicine Case Reports</i> , 2015, 14, 13-15.	0.2	10
68	Reference Values for Right Ventricular Strain in Patients without Cardiopulmonary Disease: A Prospective Evaluation and Meta-Analysis. <i>Echocardiography</i> , 2015, 32, 787-796.	0.3	79
69	Whither Anticoagulation in Pulmonary Arterial Hypertension?. <i>Circulation</i> , 2015, 132, 2360-2362.	1.6	8
70	Pulmonary Hypertension in Chronic Heart and Lung Disease. <i>Respiratory Medicine</i> , 2015, , 93-113.	0.1	1
71	Imatinib in Pulmonary Arterial Hypertension: Kit Inhibition. <i>Pulmonary Circulation</i> , 2014, 4, 452-455.	0.8	35
72	Physician Attitudes toward Palliative Care for Patients with Pulmonary Arterial Hypertension: Results of a Cross-Sectional Survey. <i>Pulmonary Circulation</i> , 2014, 4, 504-510.	0.8	42

#	ARTICLE	IF	CITATIONS
73	Hemodynamic Ranges During Daily Activities and Exercise Testing in Patients With Pulmonary Arterial Hypertension. <i>Journal of Cardiac Failure</i> , 2014, 20, 485-491.	0.7	11
74	Conversion From Sildenafil to Tadalafil. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 550-557.	1.0	14
75	Early Trends in N-Terminal Pro-Brain Natriuretic Peptide Values After Left Ventricular Assist Device Implantation for Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2014, 114, 1257-1263.	0.7	10
76	Cardiac and Lung Transplantation. , 2014, , 291-303.		0
77	PH Grand Rounds: Puzzling Etiology of Pulmonary Hypertension Resolved. <i>Advances in Pulmonary Hypertension</i> , 2014, 13, 65-67.	0.1	0
78	Survival in pulmonary arterial hypertension patients awaiting lung transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 1179-1186.	0.3	42
79	Impaired Left Ventricular Mechanics in Pulmonary Arterial Hypertension. <i>Circulation: Heart Failure</i> , 2013, 6, 748-755.	1.6	106
80	Definitions and Diagnosis of Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D42-D50.	1.2	1,467
81	A Possible Role for Systemic Hypoxia in the Reactive Component of Pulmonary Hypertension in Heart Failure. <i>Journal of Cardiac Failure</i> , 2013, 19, 50-59.	0.7	11
82	Readmissions After Implantation of Axial Flow Left Ventricular Assist Device. <i>Journal of the American College of Cardiology</i> , 2013, 61, 153-163.	1.2	209
83	Role of Serial Quantitative Assessment of Right Ventricular Function by Strain in Pulmonary Arterial Hypertension. <i>American Journal of Cardiology</i> , 2013, 111, 143-148.	0.7	137
84	TPMT genetic variants are associated with increased rejection with azathioprine use in heart transplantation. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 658-665.	0.7	17
85	Outcome Prediction by Quantitative Right Ventricular Function Assessment in 575 Subjects Evaluated for Pulmonary Hypertension. <i>Circulation: Cardiovascular Imaging</i> , 2013, 6, 711-721.	1.3	349
86	A Multicenter, Retrospective Study of Patients with Pulmonary Arterial Hypertension Transitioned from Parenteral Prostacyclin Therapy to Inhaled Iloprost. <i>Pulmonary Circulation</i> , 2013, 3, 381-388.	0.8	14
87	Pericardial Effusions in Pulmonary Arterial Hypertension. <i>Chest</i> , 2013, 144, 1530-1538.	0.4	81
88	Donor-Specific Antibodies to Class II Antigens Are Associated With Accelerated Cardiac Allograft Vasculopathy. <i>Transplantation</i> , 2013, 95, 389-396.	0.5	65
89	Combined Heart and Liver Transplant Attenuates Cardiac Allograft Vasculopathy Compared with Isolated Heart Transplantation. <i>Transplantation</i> , 2013, 95, 859-865.	0.5	35
90	Sirolimus as Primary Immunosuppression Attenuates Allograft Vasculopathy With Improved Late Survival and Decreased Cardiac Events After Cardiac Transplantation. <i>Circulation</i> , 2012, 125, 708-720.	1.6	105

#	ARTICLE	IF	CITATIONS
91	Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C) Tj ETQq1 1 0784314 031 /Over	1.2	167
92	Changes in Renal Function After Implantation of Continuous-Flow Left Ventricular Assist Devices. Journal of the American College of Cardiology, 2012, 59, 26-36.	0.7	56
93	Usefulness of the Six-Minute Walk Test After Continuous Axial Flow Left Ventricular Device Implantation to Predict Survival. American Journal of Cardiology, 2012, 110, 1322-1328.	0.3	17
94	Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1. Journal of Heart and Lung Transplantation, 2012, 31, 811-816.	0.3	210
95	World Health Organization Pulmonary Hypertension Group 2: Pulmonary hypertension due to left heart disease in the adult—a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. Journal of Heart and Lung Transplantation, 2012, 31, 913-933.	0.3	64
96	Symptom burden, quality of life, and attitudes toward palliative care in patients with pulmonary arterial hypertension: Results from a cross-sectional patient survey. Journal of Heart and Lung Transplantation, 2012, 31, 1102-1108.	1.0	1
97	Diagnostic Dilemmas in Pulmonary Hypertension. Heart Failure Clinics, 2012, 8, 331-352.	1.8	14
98	Development of prognostic tools in pulmonary arterial hypertension: Lessons from modern day registries. Thrombosis and Haemostasis, 2012, 108, 1049-1060.	0.4	448
99	The REVEAL Registry Risk Score Calculator in Patients Newly Diagnosed With Pulmonary Arterial Hypertension. Chest, 2012, 141, 354-362.	0.7	17
100	A Pulmonary Hypertension Gas Exchange Severity (PH-GXS) Score to Assist With the Assessment and Monitoring of Pulmonary Arterial Hypertension. American Journal of Cardiology, 2012, 109, 1066-1072.	1.2	1
101	Donor Pre-Treatment With Dopamine. Journal of the American College of Cardiology, 2011, 58, 1778-1779.	1.2	13
102	Treadmill testing improves survival prediction models in pulmonary arterial hypertension. American Heart Journal, 2011, 162, 1011-1017.	0.3	38
103	The usefulness of submaximal exercise gas exchange to define pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2011, 30, 1133-1142.	0.3	12
104	Cardiac allograft hypertrophy is associated with impaired exercise tolerance after heart transplantation. Journal of Heart and Lung Transplantation, 2011, 30, 1153-1160.	0.4	124
105	Integration of Clinical and Hemodynamic Parameters in the Prediction of Long-term Survival in Patients With Pulmonary Arterial Hypertension. Chest, 2011, 139, 1285-1293.	0.3	52
106	Combined Heart and Kidney Transplantation Provides an Excellent Survival and Decreases Risk of Cardiac Cellular Rejection and Coronary Allograft Vasculopathy. Transplantation Proceedings, 2011, 43, 1871-1876.	0.4	298
107	Right Ventricular Strain for Prediction of Survival in Patients With Pulmonary Arterial Hypertension. Chest, 2011, 139, 1299-1309.	1.3	106
108	Echocardiographic Variables After Left Ventricular Assist Device Implantation Associated With Adverse Outcome. Circulation: Cardiovascular Imaging, 2011, 4, 648-661.		



#	ARTICLE	IF	CITATIONS
109	Hemodynamic monitoring in pulmonary arterial hypertension. Expert Review of Respiratory Medicine, 2011, 5, 173-178.	1.0	7
110	The Usefulness of Submaximal Exercise Gas Exchange in Pulmonary Arterial Hypertension: A Case Series. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2010, 4, 117954842020100.	0.5	3
111	Response to Letter Regarding Article, "Impact of Implantable Cardioverter-Defibrillator, Amiodarone, and Placebo on the Mode of Death in Stable Patients With Heart Failure: Analysis From the Sudden Cardiac Death in Heart Failure Trial". Circulation, 2010, 122, .	1.6	1
112	Predicting Survival in Pulmonary Arterial Hypertension. Circulation, 2010, 122, 164-172.	1.6	1,353
113	B-Type Natriuretic Peptide Levels and Continuous-Flow Left Ventricular Assist Devices. ASAIO Journal, 2010, 56, 527-531.	0.9	21
114	Causes of Breathing Inefficiency During Exercise in Heart Failure. Journal of Cardiac Failure, 2010, 16, 835-842.	0.7	65
115	The usefulness of submaximal exercise gas exchange in pulmonary arterial hypertension: a case series. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2010, 4, 35-40.	0.5	3
116	Cardiac Allograft Remodeling After Heart Transplantation Is Associated with Increased Graft Vasculopathy and Mortality. American Journal of Transplantation, 2009, 9, 132-139.	2.6	34
117	Impact of Implantable Cardioverter-Defibrillator, Amiodarone, and Placebo on the Mode of Death in Stable Patients With Heart Failure. Circulation, 2009, 120, 2170-2176.	1.6	213
118	Features of Cardiac Allograft Coronary Endothelial Dysfunction. American Journal of Cardiology, 2009, 103, 1154-1158.	0.7	6
119	The effects of sildenafil and acetazolamide on breathing efficiency and ventilatory control during hypoxic exercise. European Journal of Applied Physiology, 2009, 106, 509-515.	1.2	19
120	Acute Cellular Rejection and the Subsequent Development of Allograft Vasculopathy After Cardiac Transplantation. Journal of Heart and Lung Transplantation, 2009, 28, 320-327.	0.3	141
121	Combined Heart and Liver Transplantation: A Single-Center Experience. Transplantation, 2009, 88, 219-225.	0.5	118
122	Influence of sildenafil on lung diffusion during exposure to acute hypoxia at rest and during exercise in healthy humans. European Journal of Applied Physiology, 2008, 103, 421-430.	1.2	34
123	Continuous Hemodynamic Monitoring in Patients With Pulmonary Arterial Hypertension. Journal of Heart and Lung Transplantation, 2008, 27, 780-788.	0.3	36
124	Autologous Stem Cell Transplant after Heart Transplant for Light Chain (AL) Amyloid Cardiomyopathy. Journal of Heart and Lung Transplantation, 2008, 27, 823-829.	0.3	117
125	The Effects of Nesiritide on Renal Function and Diuretic Responsiveness in Acutely Decompensated Heart Failure Patients With Renal Dysfunction. Journal of Cardiac Failure, 2008, 14, 267-275.	0.7	37
126	Bosentan for pulmonary hypertension and other pulmonary diseases: emerging evidence. Future Cardiology, 2008, 4, 459-468.	0.5	0



#	ARTICLE	IF	CITATIONS
127	Sirolimus As Primary Immunosuppressant Reduces Left Ventricular Mass and Improves Diastolic Function of the Cardiac Allograft. <i>Transplantation</i> , 2008, 86, 1395-1400.	0.5	45
128	Lipoprotein-Associated Phospholipase A2 Predicts Progression of Cardiac Allograft Vasculopathy and Increased Risk of Cardiovascular Events in Heart Transplant Patients. <i>Transplantation</i> , 2008, 85, 963-968.	0.5	16
129	Ambulatory Hemodynamic Monitoring in Pulmonary Arterial Hypertension. <i>Advances in Pulmonary Hypertension</i> , 2008, 7, 405-410.	0.1	1
130	The effects of sildenafil and acetazolamide on breathing efficiency during hypoxic exercise. <i>FASEB Journal</i> , 2008, 22, 1173.13.	0.2	0
131	Right Ventricular Pressure Waveform and Wave Reflection Analysis in Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2007, 132, 37-43.	0.4	40
132	Conversion to Sirolimus as Primary Immunosuppression Attenuates the Progression of Allograft Vasculopathy After Cardiac Transplantation. <i>Circulation</i> , 2007, 116, 2726-2733.	1.6	162
133	Replacement of Calcineurin-Inhibitors With Sirolimus as Primary Immunosuppression in Stable Cardiac Transplant Recipients. <i>Transplantation</i> , 2007, 84, 467-474.	0.5	73
134	Effects of acute changes in pulmonary wedge pressure on periodic breathing at rest in heart failure patients. <i>American Heart Journal</i> , 2007, 153, 104.e1-104.e7.	1.2	47
135	Repeat length polymorphism of the serotonin transporter gene influences pulmonary artery pressure in heart failure. <i>American Heart Journal</i> , 2007, 153, 426-432.	1.2	30
136	Baseline and Serial Neurohormones in Patients With Congestive Heart Failure Treated With and Without Bucindolol: Results of the Neurohumoral Substudy of the Beta-Blocker Evaluation of Survival Study (BEST). <i>Journal of Cardiac Failure</i> , 2007, 13, 437-444.	0.7	17
137	Systemic Inflammation and Metabolic Syndrome in Cardiac Allograft Vasculopathy. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, 826-833.	0.3	55
138	Right ventricular function with hypoxic exercise: effects of sildenafil. <i>European Journal of Applied Physiology</i> , 2007, 102, 87-95.	1.2	27
139	Portopulmonary hypertension: Results from a 10-year screening algorithm. <i>Hepatology</i> , 2006, 44, 1502-1510.	3.6	322
140	Relation of Tissue Displacement and Strain to Invasively Determined Right Ventricular Stroke Volume. <i>American Journal of Cardiology</i> , 2005, 96, 1173-1178.	0.7	79
141	Sirolimus in Cardiac Transplantation: Use as a Primary Immunosuppressant in Calcineurin Inhibitor-induced Nephrotoxicity. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 2129-2136.	0.3	90
142	Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure. <i>American Heart Journal</i> , 2005, 149, 541-547.	1.2	54
143	Immediate and Long-term Hemodynamic and Clinical Effects of Sildenafil in Patients With Pulmonary Arterial Hypertension Receiving Vasodilator Therapy. <i>Mayo Clinic Proceedings</i> , 2003, 78, 1207-1213.	1.4	109
144	Effects of the oral endothelin-receptorantagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1380-1386.	1.2	334

#	ARTICLE	IF	CITATIONS
145	Clinical predictors of exercise capacity 1 year after cardiac transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2003, 22, 16-27.	0.3	62
146	Myocardial Contractile Reserve by Dobutamine Stress Echocardiography Predicts Improvement in Ejection Fraction With $\beta$ -Blockade in Patients With Heart Failure. <i>Circulation</i> , 2003, 108, 2336-2341.	1.6	63
147	Endothelial Progenitor Cells Are Decreased in Blood of Cardiac Allograft Patients With Vasculopathy and Endothelial Cells of Noncardiac Origin Are Enriched in Transplant Atherosclerosis. <i>Circulation</i> , 2003, 108, 143-149.	1.6	142
148	Partial Normalization of the Heart Rate Response to Exercise After Cardiac Transplantation: Frequency and Relationship to Exercise Capacity. <i>Mayo Clinic Proceedings</i> , 2002, 77, 1295-1300.	1.4	38
149	Beta blockade in patients with congestive heart failure. <i>Postgraduate Medicine</i> , 2000, 108, 103-118.	0.9	5
150	Heart transplantation for radiation-associated end-stage heart failure. <i>Transplant International</i> , 2000, 13, 162-165.	0.8	21
151	Accuracy of Doppler Echocardiography in the Assessment of Pulmonary Hypertension in Liver Transplant Candidates. <i>Liver Transplantation</i> , 2000, 6, 453-458.	1.3	176
152	Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension. <i>Hepatology</i> , 1999, 30, 641-648.	3.6	271
153	Recipient Selection and Management Before Cardiac Transplantation. <i>American Journal of the Medical Sciences</i> , 1997, 314, 139-152.	0.4	0
154	Recipient Selection and Management Before Cardiac Transplantation. <i>American Journal of the Medical Sciences</i> , 1997, 314, 139-152.	0.4	18
155	EFFECTS OF PENTOXIFYLLINE ON RENAL FUNCTION AND BLOOD PRESSURE IN CARDIAC TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 1997, 63, 1607-1610.	0.5	11
156	Increase in Total Plasma Homocysteine Concentration After Cardiac Transplantation. <i>Mayo Clinic Proceedings</i> , 1995, 70, 125-131.	1.4	58
157	Techniques of Immunosuppression After Cardiac Transplantation. <i>Mayo Clinic Proceedings</i> , 1992, 67, 586-595.	1.4	11
158	The Pharmacokinetics of Racemic Verapamil in Patients with Impaired Renal Function. <i>Journal of Clinical Pharmacology</i> , 1991, 31, 45-53.	1.0	11